These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 29126357)
1. Successful treatment of high-grade pancreatic neuroendocrine neoplasms with everolimus. Genç CG; Klümpen HJ; Denecke T; Wiedenmann B; Pavel M Acta Oncol; 2018 May; 57(5):686-688. PubMed ID: 29126357 [No Abstract] [Full Text] [Related]
2. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan. Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443 [TBL] [Abstract][Full Text] [Related]
3. Everolimus in Pancreatic Neuroendocrine Carcinomas G3. Panzuto F; Rinzivillo M; Spada F; Antonuzzo L; Ibrahim T; Campana D; Fazio N; Delle Fave G Pancreas; 2017 Mar; 46(3):302-305. PubMed ID: 28099254 [TBL] [Abstract][Full Text] [Related]
4. Successful mTOR inhibitor therapy for a metastastic neuroendocrine tumour in a patient with a germline TSC2 mutation. Schrader J; Henes FO; Perez D; Burdak-Rothkamm S; Stein A; Izbicki JR; Lohse AW Ann Oncol; 2017 Apr; 28(4):904-905. PubMed ID: 28327903 [No Abstract] [Full Text] [Related]
5. Early Response to Everolimus Therapy Detected on 68Ga-DOTATATE PET/CT in a Patient With Pancreatic Neuroendocrine Tumor. Ozkan E; Soydal C; Ucak Semirgin S; Yapici O; Atmaca A; Demirag G Clin Nucl Med; 2016 Jul; 41(7):561-3. PubMed ID: 27163457 [TBL] [Abstract][Full Text] [Related]
6. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial. Lombard-Bohas C; Yao JC; Hobday T; Van Cutsem E; Wolin EM; Panneerselvam A; Stergiopoulos S; Shah MH; Capdevila J; Pommier R Pancreas; 2015 Mar; 44(2):181-9. PubMed ID: 25479584 [TBL] [Abstract][Full Text] [Related]
7. Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus. Viúdez A; Crespo G; Gómez Dorronsoro ML; Arozarena I; Marín-Méndez JJ; Custodio A; Benavent M; Goñi S; García-Paredes B; Hernando J; Durantez M; Alonso V; Riesco MDC; López C; Jiménez-Fonseca P; San Vicente BL; González-Borja I; Sevilla I; Hernández-Garcia I; Carmona-Bayonas A; Capdevila J; Pérez-Sanz J; García-Carbonero R; Pérez-Ricarte L; Llanos M; Vera R; De Jesús Acosta A Pancreatology; 2021 Jan; 21(1):215-223. PubMed ID: 33358592 [TBL] [Abstract][Full Text] [Related]
8. Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors. Pavel ME; Chen D; He W; Cushman S; Voi M; de Vries EGE; Baudin E; Yao JC Pancreas; 2017 Jul; 46(6):751-757. PubMed ID: 28609362 [TBL] [Abstract][Full Text] [Related]
9. Role of everolimus in pancreatic neuroendocrine tumors. Goldstein R; Meyer T Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937 [TBL] [Abstract][Full Text] [Related]
10. mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors. Falletta S; Partelli S; Rubini C; Nann D; Doria A; Marinoni I; Polenta V; Di Pasquale C; Degli Uberti E; Perren A; Falconi M; Zatelli MC Endocr Relat Cancer; 2016 Nov; 23(11):883-891. PubMed ID: 27697900 [TBL] [Abstract][Full Text] [Related]
11. Impact of everolimus on Japanese patients with advanced pancreatic neuroendocrine neoplasms. Lee L; Ito T; Igarashi H; Ueda K; Fujiyama T; Kawabe K; Ogawa Y J Hepatobiliary Pancreat Sci; 2017 Feb; 24(2):95-102. PubMed ID: 27926987 [TBL] [Abstract][Full Text] [Related]
12. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. Pusceddu S; Vernieri C; Di Maio M; Marconcini R; Spada F; Massironi S; Ibrahim T; Brizzi MP; Campana D; Faggiano A; Giuffrida D; Rinzivillo M; Cingarlini S; Aroldi F; Antonuzzo L; Berardi R; Catena L; De Divitiis C; Ermacora P; Perfetti V; Fontana A; Razzore P; Carnaghi C; Davì MV; Cauchi C; Duro M; Ricci S; Fazio N; Cavalcoli F; Bongiovanni A; La Salvia A; Brighi N; Colao A; Puliafito I; Panzuto F; Ortolani S; Zaniboni A; Di Costanzo F; Torniai M; Bajetta E; Tafuto S; Garattini SK; Femia D; Prinzi N; Concas L; Lo Russo G; Milione M; Giacomelli L; Buzzoni R; Delle Fave G; Mazzaferro V; de Braud F Gastroenterology; 2018 Aug; 155(2):479-489.e7. PubMed ID: 29655834 [TBL] [Abstract][Full Text] [Related]
13. New target therapies for patients with neuroendocrine tumors of the pancreas. Baltogiannis G; Katsios C; Roukos DH Expert Rev Gastroenterol Hepatol; 2011 Oct; 5(5):563-6. PubMed ID: 21910571 [No Abstract] [Full Text] [Related]
14. Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea. Lee KJ; Cho JH; Lee SH; Song SY; Lee KH; Jeong S; Ryu JK; Woo SM; Bang S; Lee JK; Lee TH; Paik WH; Kim YT; Lee WJ Cancer Chemother Pharmacol; 2017 Oct; 80(4):799-805. PubMed ID: 28884280 [TBL] [Abstract][Full Text] [Related]
15. Treatment Patterns and Burden of Illness in Patients Initiating Targeted Therapy or Chemotherapy for Pancreatic Neuroendocrine Tumors. Broder MS; Chang E; Reddy SR; Neary MP Pancreas; 2017 Aug; 46(7):891-897. PubMed ID: 28697129 [TBL] [Abstract][Full Text] [Related]
16. Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET). De Gennaro Colonna V; Pavanello C; Rusconi F; Sartore-Bianchi A; Siena S; Castelnuovo S; Sirtori CR; Mombelli G J Clin Pharm Ther; 2018 Feb; 43(1):114-116. PubMed ID: 28730672 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor. Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928 [TBL] [Abstract][Full Text] [Related]
18. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors. Martins D; Spada F; Lambrescu I; Rubino M; Cella C; Gibelli B; Grana C; Ribero D; Bertani E; Ravizza D; Bonomo G; Funicelli L; Pisa E; Zerini D; Fazio N; Target Oncol; 2017 Oct; 12(5):611-622. PubMed ID: 28634872 [TBL] [Abstract][Full Text] [Related]
19. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors. Raj N; Reidy-Lagunes D Hematol Oncol Clin North Am; 2016 Feb; 30(1):119-33. PubMed ID: 26614372 [TBL] [Abstract][Full Text] [Related]
20. Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes. Pusceddu S; Buzzoni R; Vernieri C; Concas L; Marceglia S; Giacomelli L; Milione M; Leuzzi L; Femia D; Formisano B; Mazzaferro V; de Braud F Future Oncol; 2016 May; 12(10):1251-60. PubMed ID: 26890290 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]